Drug producer Lupin on Monday said it has gotten an Establishment Inspection Report (EIR) from the US wellbeing controller for its assembling plant in Nagpur.

The <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.fda.gov/home">US Food and Drug Administration (USFDA) issues an EIR to an organization when an assessment is sufficiently shut.</a></span>

The wellbeing controller had assessed the organization's Nagpur producing office between January 6 and January 10, 2020, Lupin Ltd said in an announcement.

"We are extremely glad to have gotten the EIR for our Nagpur office, our biggest and most progressive oral strong measurement office. We stay focused on upgrading consistence and quality benchmarks over the entirety of our assembling locales," <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.lupin.com/our-world/management-and-board-of-directors/">Lupin Managing Director Nilesh Gupta said.</a></span>

This story has been distributed from a wire office feed without alterations to the content. Just the feature has been changed.